On October 15, 2024, Blake Borgeson, Director at Recursion Pharmaceuticals Inc (RXRX, Financial), executed a sale of 11,447 shares of the company. The transaction was filed on the same day through an SEC Filing. Following this transaction, the insider now owns 7,089,007 shares of Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a biotechnology firm that utilizes an AI-driven platform to decode biology and radically improve lives. The company is engaged in the discovery of treatments for rare genetic diseases and other conditions.
Over the past year, Blake Borgeson has sold a total of 352,747 shares and has not made any purchases of the company's stock. This recent sale is part of a broader trend observed within the company, where there have been 67 insider sells and no insider buys over the past year.
Shares of Recursion Pharmaceuticals Inc were priced at $6.67 on the day of the transaction. The company currently holds a market cap of approximately $1.91 billion.
The stock's valuation metrics, such as the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with historical multiples, have been considered in the calculation of the GF Value. The GF Value for Recursion Pharmaceuticals Inc is estimated at $13.19, suggesting that the stock is currently undervalued with a price-to-GF-Value ratio of 0.51, indicating a possible value trap scenario where investors should think twice.
This sale by the insider might reflect personal financial management rather than a commentary on the company's future prospects. Investors are advised to consider broader market conditions and company fundamentals alongside insider behaviors when making investment decisions.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
